Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on... see more

CSE:QNTM - Post Discussion

Quantum BioPharma Ltd > For those that are new here
View:
Post by DavidRosenberg on Nov 18, 2021 5:50pm

For those that are new here

FSD Pharma is bringing innovative neuro and  inflammatory disorders therapies to millions of patients in need

FSD Pharma is a biopharmaceutical company, with three pipelines under development in the areas of neuro and inflammatory disorders. The company’s global aspirations will be reflected through its world-class team, and its pursuit of solutions for healthcare challenges of the present and future. The company will focus on developing the assets in three therapeutic areas, and acquire assets to augment the efforts to complete phase-2 clinical trials, and enter phase-3 clinical trials. The company will look for opportunities to strategically integrate artificial intelligence and sustainability for innovative therapeutic solutions, while pursuing its mission. The company will continually evaluate its direction and explore opportunities to strengthen its mission and the pipeline

FSD Pharma has the following 3 drug candidates in its pipeline:

  • Lucid-PSYCH: a unique psychedelic molecule currently undergoing IND-enabling studies with a targeted treatment for neuropsychiatric disorders, such as Major Depressive Disorder.
  • Lucid-MS: a patented, proprietary neuroprotective new chemical entity (NCE) that has demonstrated in preclinical models the potential to reverse and prevent myelin degradation, an underlying cause of Multiple Sclerosis and other neurodegenerative orders.
  • FSD-PEA: an ultra-micro-PEA compound with the potential to address a range of inflammatory conditions. FSD-PEA has completed phase-1 FDA approved trials with positive topline results, and indications for phase-2 are currently being evaluated.

Armed with a strong balance sheet, solid pipeline, and renowned clinical team, FSD intends to advance its lead drug candidates through clinical trials with the goal of providing therapies to the millions suffering from neurodegenerative and neuropsychiatric conditions.

Additional FSD Highlights

  • A strong balance sheet represented by no debt and over USD$43.2 million in cash as of June 30, 2021.
  • Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models
  • Well-positioned to advance current pipeline and aggressively pursue additional acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on “Total Brain Health”.
  • Renowned clinical team led by Dr. Lakshmi P. Kotra, Senior Scientist at Krembil Brain Institute, University Health Network (UHN), and Professor of Medicinal Chemistry at the University of Toronto. Dr. Kotra serves as CEO of FSD Pharma’s wholly-owned subsidiary, Lucid Psycheceuticals.

With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS and Depression, FSD Pharma is on a strong trajectory for growth.

Relevant articles/videos:

FSD Pharma ‘excited’ to acquire pharma group Lucid Psycheceuticals to complement existing efforts

FSD Pharma to continue opportunistic acquisitions in endocannabinoid and psychedelic segments – executive

FSD Pharma, Developing Treatments for Mental Health Disorders

 
Comment by Mil_Man54 on Nov 18, 2021 5:58pm
That's 11 pumper posts Rosenberg...and for those new here....DavidRosenberg cannot be trusted....he is a pumper who posts misinformation and cherry picks data to mislead investors into believing FSD is in a better state than it actaully is....he will consistently make unforunded accussations that those who call him out are paid bashers and short sellers as he cannot dispute anything that we ...more  
Comment by DavidRosenberg on Nov 18, 2021 6:17pm
Sharing company updates is not reliable source of information?  What is then ? a palm reader? Mil_man54 cannot be trusted he is a paid basher who never mentions the positive developments at the company he will mislead your into thinking im a paid pumper which im not Im a shareholder , milman is the one making unfounded acusations , i will always update real shareholders whenever possible ...more  
Comment by Mil_Man54 on Nov 18, 2021 7:27pm
Good effort Rosenberg....but no one is buying or ever bought the paid basher shortseller thing....and all anyone has to do is go to first few posts 3 yrs ago to see that I am an actual investor.....and what Rosenberg considers paid PR put out by FSD as reliable information....is a source of some information but should always be suspect....when it sounds to good to be true....it usually is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities